Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The response of human melanocytic nevi to simulated solar radiation assessed by single-nucleus RNA sequencing of frozen tissue.

The Journal of investigative dermatology·2026
Same author

Tobacco and Nicotine Dependence Vulnerability as a Function of Dopaminergic Dysregulation: Proposing a Novel Strategy to Promote Neurotransmitter Homeostasis.

Current neuropharmacology·2026
Same author

Spectral EEG-guided adaptive neuromodulation for social anxiety disorder, performance-only subtype: a case report.

Frontiers in psychiatry·2026
Same author

Opioid-Induced Nodding-Not a Nice Nap.

Acta scientific neurology·2026
Same author

Corrigendum to "Selective upregulation of fatty acid-binding protein 5 within the basolateral amygdala blunts stress-induced reinstatement of cocaine-seeking behavior in mice" [Neurosci. Lett. 878 (2026) 138558].

Neuroscience letters·2026
Same author

Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?

British journal of healthcare and medical research·2026
Same journal

Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and Present.

Journal of addiction psychiatry·2025
Same journal

Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy.

Journal of addiction psychiatry·2024
Same journal

Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders.

Journal of addiction psychiatry·2024
Same journal

Is There a Natural, Non-addictive, and Non-anti-reward, Safe, Gene-based Solution to Treat Reward Deficiency Syndrome? KB220 Variants vs GLP-1 Analogs.

Journal of addiction psychiatry·2024
Same journal

Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.

Journal of addiction psychiatry·2024
Same journal

Are We Getting High Cause the Thrill is Gone?

Journal of addiction psychiatry·2024
See all related articles

Related Experiment Video

Updated: May 28, 2025

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.1K

Complex NADASE Infusions Improve Clinical Outcome in Substance Use Disorder: Descriptive Annotation in Fifty Cases.

Kenneth Blum1,2,3,4,5,6,7, Thomas Mclaughlin2,3, Kai Uwe Lewandrowski5,8,9

  • 1Division of Addiction Research and Education, Center for Sports, Exercise and Mental Health, Western University Health Sciences, Pomona, USA.

Journal of Addiction Psychiatry
|February 14, 2025
PubMed
Summary
This summary is machine-generated.

Nicotinamide adenine dinucleotide (NAD+) infusions show significant reductions in craving, anxiety, and depression for substance use disorder patients. This treatment also led to negative drug tests in 100% of patients tested.

Keywords:
Anxiety depressionCravingsDopamine homeostasisMedication assistant treatmentNADASENicotinamide adenine dinucleotide infusionsReward deficiency syndrome

More Related Videos

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.1K
Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

3.0K

Related Experiment Videos

Last Updated: May 28, 2025

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.1K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.1K
Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

3.0K

Area of Science:

  • Neuroscience
  • Addiction Medicine
  • Biochemistry

Background:

  • Substance Use Disorder (SUD) presents a significant public health challenge.
  • Current treatments for SUD often have limited efficacy, especially for poly-drug abusers.
  • Nicotinamide adenine dinucleotide (NAD+) is a vital coenzyme with potential therapeutic applications.

Purpose of the Study:

  • To evaluate the efficacy of NAD+ infusions in treating SUD.
  • To assess the impact of NAD+ and other supplements on craving and psychiatric symptoms in poly-drug abusers.
  • To provide clinical evidence for NAD+ as a treatment modality for substance dependency.

Main Methods:

  • A cohort of 50 treatment-resistant SUD patients received a minimum of 7 NAD+ infusions over four weeks.
  • Infusions included NAD+, amino acids (d-phenylalanine, glycine), ananylglutamine dipeptide, and Myer's cocktail (B complex).
  • Patient outcomes were measured using Likert scales for craving, anxiety, depression, and sleep, with counselor-administered interviews.

Main Results:

  • Significant reductions in craving scores (P = 1.063E-9), anxiety (P = 5.487E-7), and depression (P = 1.763E-4) were observed post-infusion.
  • A non-significant trend towards improved sleep duration was noted (6.28 to 7.34 hours).
  • 100% of patients tested (n=40) during infusions showed negative results for illicit drugs.

Conclusions:

  • NAD+ infusions demonstrate significant efficacy in reducing core SUD symptoms like craving, anxiety, and depression.
  • The safety profile of NAD+ infusions is supported by approximately 1,000 procedures performed without serious adverse events.
  • This study contributes to the growing evidence base for NAD+ as a viable therapeutic option for substance use disorder.